Notis McConarty Edward Sells 7,116 Shares of Becton, Dickinson and Company $BDX

Notis McConarty Edward decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 79.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,790 shares of the medical instruments supplier’s stock after selling 7,116 shares during the quarter. Notis McConarty Edward’s holdings in Becton, Dickinson and Company were worth $308,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in BDX. GQG Partners LLC bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at approximately $689,833,000. Vanguard Group Inc. lifted its position in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the period. Nuveen LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $211,097,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $155,080,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BDX. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a research report on Thursday, September 25th. They set a “sector perform” rating and a $211.00 target price for the company. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $205.40.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,023 shares of company stock valued at $562,036 over the last ninety days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $193.85 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a market capitalization of $55.56 billion, a PE ratio of 34.87, a price-to-earnings-growth ratio of 1.50 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The business has a 50 day simple moving average of $189.65 and a 200 day simple moving average of $186.88.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same period last year, the firm posted $3.50 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.